title: High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
authors.affiliation: Department of Hematology, University of Münster, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: C
authors.initials: C
authors.lastname: Aul
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
authors.forename: R
authors.initials: R
authors.lastname: Schönrock-Nabulsi
authors.forename: W D
authors.initials: WD
authors.lastname: Ludwig
authors.forename: A
authors.initials: A
authors.lastname: Bartholomäus
authors.forename: P
authors.initials: P
authors.lastname: Bettelheim
authors.forename: K
authors.initials: K
authors.lastname: Becker
authors.forename: L
authors.initials: L
authors.lastname: Balleisen
authors.forename: B
authors.initials: B
authors.lastname: Lathan
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011446:Prospective Studies; D012008:Recurrence
chemical_list: D003561:Cytarabine; D008942:Mitoxantrone